Autoimmune aspects of vitiligo

Autoimmunity

Volumn 34, Issue 1, 2001, Pages 65-77

  Kemp, E H ^a   Waterman, E A ^a   Weetman, A P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Autoantibody; Autoantigen; Autoimmunity; T cell; Vitiligo

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CELL ANTIGEN; CORTICOSTEROID DERIVATIVE; CYTOKINE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; PSORALEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; DEPIGMENTATION; DISEASE ASSOCIATION; DISEASE MODEL; EPIDERMIS; HASHIMOTO DISEASE; HUMAN; HUMORAL IMMUNITY; HYPOPIGMENTATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LANGERHANS CELL; MELANOCYTE; NONHUMAN; REVIEW; SERUM; T LYMPHOCYTE; ULTRAVIOLET A RADIATION; VITILIGO;

EID: 0034826585     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916930108994127     Document Type: Review

References (139)

1. Auditologic abnormalities in cases of vitiligo
2. Pigment cells of the eyes in people with vitiligo
3. Prevalence of vitiligo: Epidemiological survey on the Isle of Bornholm, Denmark
4. Epidemiologic study of vitiligo in Surat area, South Gujarat
5. Pattern of familial aggregation of vitiligo
6. Vitiligo and other hypomelanoses of hair and skin
7. Psychosocial effect of vitiligo: A comparison of vitiligo patients with normal control subjects, with psoriasis patients, and with patients with other pigmentary disorders
8. Psychologic effects of vitiligo: A critical incident analysis
9. New regulation of melanin biosynthesis and autodestruction of melanoma cells
10. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo
11. Vitiligo. It is important
12. Low catalase levels in the epidermis of patients with vitiligo
13. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo
14. Morphologic observations on the dermal nerves in vitiligo: An ultrastructural study
15. Neuropeptide and neuronal marker studies in vitiligo
16. Vitiligo
17. Vitiligo in Graves' disease
18. Vitiligo and juvenile diabetes mellitus
19. Antibodies to normal human melanocytes in vitiligo
20. The significance of vitiligo antibodies
21. Review of the etiopathomechanism of vitiligo: A convergence theory
22. Vitiligo
23. Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
24. Vitiligo and disorders of the retinal pigment epithelium
25. New observations on vitiligo and ocular disease
26. Ocular disturbances in vitiligo
27. Pigmentation of the stria vascularis
28. Deafness and vitiligo
29. Profile of alopecia areata in Northern India
30. Integumentary associations of pernicious anaemia
31. Eighty-six cases of Addison's disease
32. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes
33. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients
34. Vitiligo, thyroid disease and autoimmunity
35. The spectrum of thyroid disease in the community: The Wickham survey
36. Prevalence of autoimmune atrophic gastritis in vitiligo
37. Organ-specific autoantibodies in vitiligo patients and their relatives
38. Autoantibodies in patients with vitiligo
39. Autoantibodies in vitiligo
40. Animal models of an acquired pigmentary disorder: Vitiligo
41. The Smyth chicken: A model for autoimmune amelanosis
42. Persistence of abnormal melanocytes in immunosuppressed chickens of the autoimmune "DAM" line
43. Effect of bursectomy on development of a spontaneous postnatal amelanosis
44. Effect of corticosterone on the incidence of amelanosis in Smyth delayed amelanotic line chickens
45. Enhanced integumental and ocular amelanosis following the termination of cyclosporin administration
46. T cells in regenerating feathers of Smyth line chickens in vitiligo
47. Alterations in blood leukocyte populations in Smyth line chickens with autoimmune vitiligo
48. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo
49. Smyth chicken melanocyte autoantibodies: Cross-reactivity, in vivo binding, and plasma membrane location of the antigen(s)
50. Mammalian tyrosinase-related protein-1 is recognised by autoantibodies from vitiliginous Smyth chickens
51. Antibodies to surface antigens of pigmented cells in animals with vitiligo
52. Photochemotherapy of vitiligo: Use of orally administered psoralens and a high intensity longwave ultraviolet light system
53. Vitiligo treated with topical clobetasol propionate
54. Topically administered fluorouracil in vitiligo
55. Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens -DR3 and/or -DR4, except when associated with type I autoimmune polyglandular syndrome
56. HLA-A, -B, -C and -DR antigens in patients with Graves' disease and their correlation with signs and clinical course
57. HLA-D and DR antigens in genetic analysis of insulin-dependent diabetes mellitus
58. Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak population
59. Age onset in vitiligo: Relationship with HLA seratypes
60. Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo
61. Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients
62. HLA antigens in Omani patients with vitiligo
63. HLA-DR1 is associated with vitiligo
64. Vitiligo is associated with HLA-DR4 in black patients: A preliminary report
65. Association of HLA-DR4 with vitiligo
66. Autoimmunity in vitiligo: Relationship with HLA, Gm, and Km polymorphisms
67. Vitiligo and HLA system
68. Vitiligo is associated with a significant increase in HLA-A30, Cw6, and DQw3 and a decrease in C4Q0 in northern Italian patients
69. Histocompatability antigens in vitiligo: Hamburg study on 102 patients from northern Germany
70. A new member of the immunoglobulin superfamily - CTLA-4
71. CTLA-4 mediates antigen-specific apoptosis of human T cells
72. CTLA-4 can function as a negative regulator of T cell activation
73. A CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism
74. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients
75. Dinucleotide repeat polymorphism at the human CTLA-4 gene
76. Analysis of a microsatellite polymorphism of the cytotoxic T lymphocyte antigen-4 gene in patients with vitiligo
77. Clinical laboratory methods for detection of cellular immunity
78. Vitiligo: Peripheral T-cell subset imbalance as defined by monoclonal antibodies
79. Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives
80. + T-cell and evidence of peripheral T-cell activation
81. T-cell profiles in vitiligo
82. Aberrations in T lymphocytes and natural killer cells in vitiligo: A flow cytometric study
83. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
84. An immunohistological study of cutaneous lymphocytes in vitiligo
85. Further evidence for involvement of both cell mediated and humoral immunity in generalised vitiligo
86. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance
87. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo
88. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients
89. Alterations in IL-6, IL-8, GM-CSF, TNF-a, and IFN-y release by peripheral mononuclear cells in patients with active vitiligo
90. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: Evidence for a regulatory role of IL-6, IL-7, TNF-a and UVB light
91. Granulocyte/macrophage colony-stimulating factor is an intrinsic growth factor for human melanocytes in UVA-induced melanosis
92. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
93. Langerhans cells and vitiligo: Quantitative study of T6 and HLR-DR antigen-expressing cells
94. Distribution of epidermal dendritic cells in pigmented and unpigmented skin
95. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo
96. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders
97. Molecular pathology of type I diabetes
98. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases
99. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation
100. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo
101. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo
102. Identification of pigment cell antigens defined by vitiligo antibodies
103. Characterisation of vitiligo antigens
104. The role of tyrosinase in autoimmune vitiligo
105. Tyrosinase as an autoantigen in patients with vitiligo
106. 35S-labelled recombinant human tyrosinase in a radioimmunoassay
107. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay
108. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy
109. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: Evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)
110. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: A sensitive and quantitative radioimmunoassay (RIA)
111. Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity
112. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo
113. Enhanced susceptibility of melanocytes to different immunologic effector mechanisms in vitro: Potential mechanisms for post-inflammatory hypopigmentation and vitiligo
114. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo
115. Association of IgA antimelanoma antibodies in the sera of vitiligo patients with active disease
116. Detection of antibenzene ring antibodies in patients with vitiligo
117. Vitiligo and melanoma associated hypopigmentation: A similar appearance but a different mechanism
118. The prognostic significance of vitiligo in patients with melanoma
119. Vitiligo in patients with metastatic melanoma: A good prognostic sign
120. Cutaneous depigmentary phenomena in patients with malignant melanoma
121. Gross and ultrastructural changes in a new melanoma model: The Sinclair swine
122. Antibodies to surface antigens of pigmented cells in animals with vitiligo
123. Growth and spontaneous regression of swine melanoma: Relationship of in vitro leukocyte reactivity
124. Immune mechanisms in vitiligo
125. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells
126. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients
127. The tyrosinase gene codes for an antigen recognised by autologous cytotoxic T lymphocytes on HLA-A2 melanomas
128. Identification of a gene encoding a melanoma tumor antigen recognised by HLA-A31-restricted tumor-infiltrating lymphocytes
129. Identification of TRP-2 as a human tumor antigen recognised by cytotoxic T lymphocytes
130. Melanocyte lineage-specific antigen gp100 is recognised by melanoma-derived tumor-infiltrating lymphocytes
131. A new gene coding for a differentiation antigen recognised by autologous cytotoxic T lymphocytes on HLA-A2 melanomas
132. Melanoma-associated hypopigmentation: Where are the antibodies?
133. Anti-tyrosinase antibodies in malignant melanoma
134. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
135. Tumor immunity and autoimmunity induced by immunisation with homologous DNA
136. + lymphocytes
137. Coupling and uncoupling of tumor immunity and autoimmunity
138. Vitiligo antibodies are not directed to tyrosinase
139. Identification of autoantibody to melanocytes and characterisation of vitiligo antigen in vitiligo patients